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The development of a system of plastic bags 
connected by integral tubing for the collection, 
processing and storage of blood has made it pos-
sible for selective transfusion of appropriate blood 
components. It is now possible to select the blood 
component that will correct a patient's physiologic 
deficiency. This has resulted in better patient care 
and in better utilization of blood since a single 
unit of blood can be used to supply erythrocytes for 
an anemic patient, platelets for a patient with 
thrombocytopenia and factor VIII concentrate for 
a patient with hemophilia. 
In order to utilize blood and its components 
optimally, there must be a close working arrange-
ment between the blood bank personnel and the 
clinical staff. At the time when blood is obtained 
from a donor, a decision should be made con-
cerning how the blood will be used. Several of 
the components can be prepared only from fresh 
blood. The equipment, supplies and personnel time 
should be used to produce the maximum benefit 
to the recipients of the blood. Although each unit 
of blood could be separated into several useful com-
ponents, it is a wasteful procedure if the com-
ponents are not used. Each institution must deter-
mine its need for blood and blood components . 
Those responsible for the operation of the blood 
bank should not make unilateral decisions about 
the preparation of blood components and the 
clinical staff should not make unilateral decisions 
about the use of blood components. 
Packed Red Blood Cells. When blood is col-
lected in the proper closed bag system, it is possible 
to remove much of the plasma after sedimentation 
or centrifugation without opening the container. 
The resulting packed red blood cells remain viable 
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for transfusion purposes for 21 days when stored 
under standard conditions. The obvious advantage 
of transfusing packed red blood cells is that the 
circulating erythrocyte mass of the recipient can 
be increased without increasing the circulating 
plasma volume. This minimizes the possibility of 
circulatory overload. It has been estimated that up 
to 80 percent of the transfusions should be in the 
form of packed red blood cells (2) . 
Along with the plasma, most of the sodium 
added in the anticoagulant solution is removed. This 
can be an important factor when transfusions are 
necessary in patients requiring limited sodium in-
take. In addition to the excessive amounts of elec-
trolytes and citric acid, the plasma contains anti-
bodies. One of the dangers in the universal donor 
concept is that the plasma of group O individuals 
contains antibodies against group A and group B 
cells. These antibodies are removed along with 
the plasma. Although type specific compatible 
erythrocytes are the treatment of choice, in an 
emergency situation when such blood is not avail-
able, group O packed red blood cells are an ac-
ceptable form of therapy. 
Factor VIII Concentrates. The treatment of 
hemophilia with plasma rather than whole blood 
was an early form of component therapy. It was 
found that plasma contains the material lacking in 
hemophilia and except for the occasional patient 
with anemia, whole blood is seldom needed for 
the treatment of hemophilia. Although the anti-
hemophilic factor in plasma is relatively labile, it 
can be maintained in plasma stored below -18 °C. 
Until relatively recently, plasma removed from 
whole blood within a few hours of collection and 
then promptly frozen was the only available source 
of factor VIII for human use. Because of the rela-
tively small amount of antihemophilic activity in 
plasma, large amounts of fluid had to be infused 
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to significantly increase the circulating level in the 
patient. In addition, the infused activity was re-
tained in the circulation for only a short period 
of time (4). Thus, therapy was restricted to the 
amount of fluid that could be infused without caus-
ing overload. 
In 1965, Pool and her associates (5) reported 
that when frozen plasma was thawed slowly, a 
poorly soluble, gelatinous precipitate was formed. 
This material, called cryoprecipitate, was found to 
contain a considerable amount of the antihemo-
philic activity of plasma. Thus, it became possible 
to concentrate and collect factor VIII of plasma 
in a closed bag system. The resulting material con-
tains, on the average, about half of the antihemo-
philic activity of the original plasma and in a 
relatively small volume. 
Although the treated plasma can be returned 
to the cellular component and used as whole blood, 
most have found it better to utilize the plasma for 
other purposes. The residual plasma can be used 
for all conditions where plasma is indicated other 
than for the treatment of hemophilia. 
Platelet Concentrates. Fresh whole blood con-
tains viable platelets which will function when 
transfused. When platelets are needed to control 
bleeding in a patient with thrombocytopenia, how-
ever, a large amount of blood must be infused to 
increase the platelet level in the circulation. Platelets 
can be separated from whole blood and transfused 
in a relatively small volume. 
Platelets have a specific gravity of 1.040 while 
the specific gravity of erythrocytes is about 1.095 
(3). Since platelets are lighter than erythrocytes, 
the red blood cells can be sedimented by low speed 
centrifugation while the platelets remain suspended 
in plasma. In this way platelets can be separated 
from whole blood in a closed bag system. Platelets, 
however, have a very short shelf life and to be 
effective must be infused promptly after collection. 
Although platelets lose viability rapidly, approxi-
mately half of the recovered platelets are still effec-
tive after 72 hours of storage. Most workers, though, 
feel that platelets should be used within the first 
48 hours after collection. Although there is some 
evidence that room temperature storage has some 
advantages, it is felt that best results are obtained 
when platelets are stored at 4 °C. Additional studies 
of storage are necessary to determine optimal 
conditions ( 1) . 
Platelets can be given along with the plasma 
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as platelet rich plasma. It is usually necessary, 
however, to give the platelets recovered from six 
units of blood to achieve the desired effects and it 
is normally not desirable to give this amount of 
fluid. The usual practice is to concentrate the 
platelets by centrifugation and remove all but ap-
proximately 30 ml of plasma. Following centrifuga-
tion, it may be difficult to resuspend the platelets. 
Gentle agitation after storage for about one hour 
has been found to result in a satisfactory product. 
It is generally recommended that platelets be in-
fused through a filter to remove any large 
aggregates. 
Plasmapheresis. One of the limitations of ob-
taining blood is that approximately six-to-eight 
weeks are required for the regeneration of eryth-
rocytes. For this reason, the interval between in-
dividual donations of blood should be at least eight 
weeks. The regeneration of the fluid volume and 
plasma proteins is more rapid. With a series of 
bags connected by integral tubing, it is possible to 
withdraw blood from a donor, separate the eryth-
rocytes from the platelet rich plasma and return 
the erythrocytes to the donor. This process, called 
plasmapheresis, can be repeated at frequent intervals 
without danger to the donor. 
This technique has several advantages when 
the needs for platelets and plasma are great. A 
relatively small number of donors can supply con-
siderable amounts of platelets and plasma. There 
is increasing evidence that when platelets are given 
over a prolonged period, antibodies to platelets 
develop in the multitransfused patient. These anti-
bodies appear to be directed against the histo-
compatibility antigens of the HL-A system. Those 
institutions which use platelet transfusions on a 
long-term basis have found that best platelet sur-
vival occurs when there is an HL-A compatibility 
between donor and recipient. It is generally felt 
that if a series of platelet transfusions are required, 
it is best to obtain platelets by plasmapheresis from 
a few histocompatible donors rather than utilizing 
platelets from a number of random blood donors 
(7). 
Frozen Red Blood Cells. With currently avail-
able techniques, erythrocytes retain sufficient via-
bility for transfusion purposes for only 21 days. 
For this reason blood supplies must be continuous 
and the blood bank must be able to predict its 
needs so that sufficient blood will be available and 
yet there will not be wastage due to excessive 
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amounts of erythrocytes lost by out-date. An ob-
vious solution would be to develop a method of 
preservation of blood for longer periods. 
A number of chemical additives have been 
used in an attempt to prolong the viability of 
erythrocytes. The most promising has been adenine 
(6). With the addition of adenine at the time of 
collection, there is evidence that erythrocytes re-
main viable up to 40 days under the usual storage 
conditions. At the present time, however, there is 
not sufficient evidence to be certain of the safety 
of this material for human use. 
Other workers have demonstrated that eryth-
rocytes suspended in cryoprotective solutions retain 
viability almost indefinitely when stored at low 
temperatures. Before the erythrocytes can be in-
fused , the cryoprotective materials must be removed. 
The supplies and equipment necessary for prepara-
tion, storage and washing make this technique rather 
expensive. Although the techniques are practical, 
the cost for a unit of such blood is almost pro-
hibitive for routine use. If methods can be de-
veloped to decrease the cost, there are many ad-
vantages to such a technique. 
Leukocyte-Poor Blood. There are many known 
antigens associated with erythrocytes, but most of 
these are only occasionally of clinical significance. 
For practical purposes, it is only necessary to 
routinely test for ABO and Rh antigens. In a 
similar way there are a number of antigens as-
sociated with leukocytes, but these are usually of 
little clinical significance. In multitransfused pa-
tients, however, the leukocytes may cause reactions. 
To prevent these reactions it may be necessary to 
give leukocyte-poor blood. Recently it has been 
recognized that leukocyte antigens may have an 
adverse effect on organ transplantation. It has been 
suggested that patients with chronic renal disease 
who may be candidates for renal transplantation 
should be given only leukocyte-poor blood. 
The specific gravity of granulocytes is 1.087-
1.092 and the specific gravity of lymphocytes is 
1.070 ( 3). Thus differential centrifugation to prepare 
leukocyte-poor erythrocytes is rather difficult. There 
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are techniques by which most of the leukocytes can 
be separated from erythrocytes but these techniques 
are tedious and time consuming. In order to remove 
the leukocytes and their antigens it is necessary 
that fresh blood be used. In those institutions that 
have a frozen blood program, it has been found 
that this preparation is an excellent source of 
leukocyte-poor erythrocytes. 
Summary. At the present time there are a 
number of blood components that are more suitable 
for transfusion purposes than is whole blood. In 
order to make maximum use of blood, it is neces-
sary that there be close cooperation between the 
blood bank personnel and those responsible for 
patient care. 
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